CWM
ALXN

Cabot Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Cabot Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,459
Closed -$2.14M – 159
2016
Q3 		$2.14M Sell
17,459
-12,943
-43% -$1.67M 0.55% 65
2016
Q2 		$3.55M Buy
30,402
+8,215
+37% +$1.17M 0.93% 40
2016
Q1 		$3.09M Sell
22,187
-1,457
-6% -$214K 0.86% 49
2015
Q4 		$4.51M Buy
23,644
+123
+0.5% +$21.5K 1.15% 32
2015
Q3 		$3.68M Buy
23,521
+12,956
+123% +$2.36M 1.02% 39
2015
Q2 		$1.91M Sell
10,565
-38
-0.4% -$6.56K 0.46% 79
2015
Q1 		$1.84M Sell
10,603
-11,405
-52% -$2.06M 0.45% 81
2014
Q4 		$4.07M Sell
22,008
-1,867
-8% -$346K 1% 46
2014
Q3 		$3.96M Buy
23,875
+261
+1% +$42.9K 1.01% 41
2014
Q2 		$3.69M Sell
23,614
-398
-2% -$62.8K 0.93% 47
2014
Q1 		$3.65M Sell
24,012
-13,857
-37% -$2.2M 0.96% 36
2013
Q4 		$5.03M Sell
37,869
-156
-0.4% -$18.7K 1.32% 15
2013
Q3 		$4.42M Sell
38,025
-11,974
-24% -$1.31M 1.32% 13
2013
Q2 		$4.61M Buy
+49,999
New +$4.82M 1.59% 7

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Cabot Wealth Management's ALXN Position: Q4 2016 in Review

Cabot Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2016, closing a stake of 17,459 shares — an estimated $2.14M sold.

Cabot Wealth Management first reported a position in ALXN in Q2 2013 and held it in 14 quarters. The position peaked at $5.03M in Q4 2013. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

  • Cabot Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Cabot Wealth Management sold 17,459 Alexion Pharmaceuticals shares in Q4 2016, an estimated $2.14M.
  • Cabot Wealth Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Cabot Wealth Management's Alexion Pharmaceuticals position peaked at $5.03M in Q4 2013.
  • 548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Cabot Wealth Management's 13F filing for Q4 2016, filed 7 Feb 2017.